Effect of Doxazosin GITS on Blood Pressure in Hypertensive and Normotensive Patients: A Review of Hypertension and BPH Studies

References

• Lund-Johansen P, Omvik P, Haugland H. Acute and chronic haemodynamic effects of doxazosin in hypertension at rest and during exercise. Br J Clin Pharmacol 1986; 21 Suppl 1: 45-54S.
   Google Scholar
• Grimm RJ, Flack J, Grandits G, et al. Long-term effects on plasma lipids of diet and drugs to treat hypertension. Treatment of Mild Hypertension Study (TOMBS) Research Group. JAMA 1996; 275: 1549–56.
   Google Scholar
• Shionoiri H, Ashino K, Yamanaka K, Shindo K, Hiroto S, Arita T. Effect of doxazosin therapy on glucose tolerance and lipid metabolism in hypertensive patients with impaired glucose tolerance. Clin Ther 1997; 19: 527–36.
   PubMed Web of Science ®Google Scholar
• Neaton JD, Grimm RH, Jr, Prineas RJ, et al. Treatment of Mild Hypertension Study. Final results. Treatment of Mild Hypertension Study Research Group. JAMA 1993; 270: 713–24.
   Google Scholar
• Talseth T, Westlie L, Daae L. Doxazosin and atenolol as monotherapy in mild and moderate hypertension: a randomized, parallel study with a three-year follow-up. Am Heart J 1991; 121 (1 Pt 2): 280–5.
   Google Scholar
• Wessels F. Double-blind comparison of doxazosin and enalapril in patients with mild or moderate essential hypertension. Am Heart J 1991; 121 (1 Pt 2): 299–303.
   Google Scholar
• Black HR, Sollins JS, Garofalo IL. The addition of doxazosin to the therapeutic regimen of hypertensive patients inadequately controlled with other antihypertensive medications: a randomized, placebo-controlled study. Am J Hypertens 2000; 13 (5 Pt 1): 468–74.
   Google Scholar
• Nalbantgil S, Nalbantgil I, Onder R. Clinically additive effect between doxazosin and amlodipine in the treatment of essential hypertension. Am J Hypertens 2000; 13: 921–26.
   PubMedGoogle Scholar
• Englert RG, Mauersberger H. A single-blind study of doxazosin in the treatment of essential hypertension when added to nonresponders to angiotensin-converting enzyme inhibitor therapy. Am Heart J 1988; 116(6 Pt 2): 1826–32.
   Google Scholar
• Lindner UK, von Manteuffel GE, Stafunsky M. The addition of doxazosin to the treatment regimen of hypertensive patients not responsive to nifedipine. Am Heart J 1988; 116 (6 Pt 2): 1814–20.
   Google Scholar
• Searle M, Dathan R, Dean S, Christensen CC, Westheim A. Doxazosin in combination with atenolol in essential hypertension: a double-blind placebo-controlled multicentre trial. Eur J Clin Pharmacol 1990; 39: 299–300.
   Google Scholar
• Zehetgruber M, Christ G, Gabriel H, et al. Effect of antihypertensive treatment with doxazosin on insulin sensitivity and fibrinolytic parameters. Thromb Haemost 1998; 79: 378–82.
   PubMed Web of Science ®Google Scholar
• Giorda C, Appendino M, Mason MG, Imperiale E, Pagano G. Alpha 1-blocker doxazosin improves peripheral insulin sensitivity in diabetic hypertensive patients. Metabolism 1995; 44: 673–6.
   Google Scholar
• Inoue Y, Kaku K, Kaneko T, et al. Antihypertensive and metabolic effects of doxazosin in hypertensive patients with concomitant non-insulin-dependent diabetes mellitus. J Int Med Res 1996; 24: 138–46.
   PubMed Web of Science ®Google Scholar
• Dominguez LJ, Weinberger MH, Cefalu WT, et al. Doxazosin lowers blood pressure and improves insulin responses to a glucose load with no changes in tyrosine kinase activity or insulin binding. Am J Hypertens 1995; 8 (5 Pt 1): 528–32.
   Google Scholar
• Maheux P, Facchini F, Jeppesen J, etal. Changes in glucose, insulin, lipid, lipoprotein, and apoprotein concentrations and insulin action in doxazosin-treated patients with hyperten-sion. Am J Hypertens 1994; 7: 416–24.
   PubMed Web of Science ®Google Scholar
• Giorda C, Appendino M. Effects of doxazosin, a selective alpha 1-inhibitor, on plasma insulin and blood glucose response to a glucose tolerance test in essential hyperten-sion. Metabolism 1993; 42: 1440–2.
   PubMed Web of Science ®Google Scholar
• Shieh SM, Sheu WH, Shen DC, Fuh MM, Chen YD, Reaven GM. Glucose, insulin, and lipid metabolism in doxazosin-treated patients with hypertension. Am J Hypertens 1992; 5: 827–31.
   PubMed Web of Science ®Google Scholar
• Cabo L, Davis PA, Cantaro S, et al. Effect of doxazosin in mild to moderate hypertensive patients with insulin-dependent diabetes mellitus. Acta Diabetol 1998; 35: 96–100.
   PubMed Web of Science ®Google Scholar
• Hirano T, Yoshino G, Kashiwazaki K, Adachi M. Doxazosin reduces prevalence of small dense low density lipoprotein and remnant-like particle cholesterol levels in nondiabetic and diabetic hypertensive patients. Am J Hypertens 2001; 14 (9 Pt 1): 908–13.
   Google Scholar
• Agabiti-Rosei E, Muiesan ML, Rizzoni D, et al. Reduction of left ventricular hypertrophy after longterm antihyperten-sive treatment with doxazosin. J Hum Hypertens 1992; 6: 9–15.
   Google Scholar
• Monsalve P, Vera 0, Perez Acuna F, et al. Echocardio-graphic assessment of doxazosin on left ventricular mass in patients with essential hypertension. Am Heart J 1991; 121 (1 Pt 2): 356–61.
   Google Scholar
• Corral it, Lopez NC, Pecorelli A, Rincon LA, Teran VD. Doxazosin in the treatment of mild or moderate essential hypertension: an echocardiographic study. Am Heart J 1991; 121 (1 Pt 2): 352–6.
   Google Scholar
• Christensen MM, Bendix Holme J, Rasmussen PC, et al. Doxazosin treatment in patients with prostatic obstruction. A double-blind placebo-controlled study. Scand J Urol Nephrol 1993; 27: 39–44.
   PubMed Web of Science ®Google Scholar
• Chapple CR, Carter P, Christmas TJ, et al. A three month double-blind study of doxazosin as treatment for benign prostatic bladder outlet obstruction. Br J Urol 1994; 74: 50–6.
   PubMedGoogle Scholar
• Mobley DF, Dias N, Levenstein M. Effects of doxazosin in patients with mild, intermediate, and severe benign prostatic hyperplasia. Clin Ther 1998; 20: 101–9.
   Google Scholar
• Lepor H, Kaplan S, Klimberg I, et al. Doxazosin for benign prostatic hyperplasia: long-term efficacy and safety in hypertensive and normotensive patients. J Urol 1997; 157: 525–30.
   PubMed Web of Science ®Google Scholar
• Fawzy A, Braun K, Lewis GP, Gaffney M, Ice K, Dias N. Doxazosin in the treatment of benign prostatic hyperplasia in normotensive patients: a multicenter study. J Urol 1995; 154: 105–9.
   PubMed Web of Science ®Google Scholar
• Gillenwater JY, Conn RL, Chrysant SG, etal. Doxazosin for the treatment of benign prostatic hyperplasia in patients with mild to moderate essential hypertension: a double-blind, placebo-controlled, dose-response multicenter study. J Urol 1995; 154: 110–15.
   PubMed Web of Science ®Google Scholar
• Fulton B, Wagstaff A, Sorkin E. Doxazosin. An update of its clinical pharmacology and therapeutic applications in hypertension and benign prostatic hyperplasia. Drugs 1995; 49: 295–320.
   Google Scholar
• Chung M, Vashi V, Puente J, Sweeney M, Meredith P. Clinical pharmacokinetics of doxazosin in a controlled-release gastrointestinal therapeutic system (GITS) formula-tion. Br J Clin Pharmacol 1999; 48: 678–87.
   Google Scholar
• Os I, Stokke HP. Effects of doxazosin in the gastrointestinal therapeutic system formulation versus doxazosin standard and placebo in mild-to-moderate hypertension. Doxazosin Investigators' Study Group. J Cardiovasc Pharmacol 1999; 33: 791–7.
   PubMedGoogle Scholar
• Os I, Stokke HP. Doxazosin GITS compared with doxazosin standard and placebo in patients with mild hypertension. Blood Press 1999; 8: 184–91.
   PubMed Web of Science ®Google Scholar
• Andersen M, Dahlstrand C, Hoye K. Double-blind trial of the efficacy and tolerability of doxazosin in the gastro-intestinal therapeutic system, doxazosin standard, and placebo in patients with benign prostatic hyperplasia. Eur Urol 2000; 38: 400–9.
   Google Scholar
• Gratzke P, Kirby R. Doxazosin GITS and doxazosin standard in patients with benign prostatic hyperplasia: double blind trial of efficacy and tolerability. Fortschr Med 2000 November: 83–93.
   Google Scholar
• Kirby RS, Andersen M, Gratzke P, Dahlstrand C, Hoye K. A combined analysis of double-blind trials of the efficacy and tolerability of doxazosin-gastrointestinal therapeutic system, doxazosin standard and placebo in patients with benign prostatic hyperplasia. BJU Int 2001; 87: 192–200.
   Google Scholar
• Vasan RS, Larson MG, Leip EP, et al. Impact of high-normal blood pressure on the risk of cardiovascular disease. N Engl J Med 2001; 345: 1291–7.
   PubMed Web of Science ®Google Scholar
• Kaplan SA, Meade-D'Alisera P, Quinones S, Soldo KA. Doxazosin in physiologically and pharmacologically nor-motensive men with benign prostatic hyperplasia. Urology 1995; 46: 512–17.
   Google Scholar
• Takata Y, Yoshizumi T, Ito Y, Hirota Y, Fujishima M. Doxazosin and 48-hour ambulatory blood pressure monitor-ing in normotensive subjects. Jpn Circ J 1994; 58: 403–8.
   Google Scholar
• Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihyper-tensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group. JAMA 2000; 283: 1967–75.
   PubMed Web of Science ®Google Scholar